TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00237146
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03934333
Drug: BDA MDI 160/180 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/albuterol sulfate pressurized inhalation suspension, single dose given as 2 inhalations of 80/90 mcg.
Study: NCT00433173
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transdermal 7.5 g/per day for 3 months
Study: NCT00357643
Drug: Calcium 500 mg/day and vitamin D 700 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01043068
Drug: Cancer pain management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
Study: NCT02900729
Drug: Amlodipine, losartan potassium and hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.
Study: NCT03684616
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous statin treatment for 3 months prior to cardiac arrest
Study: NCT00775138
Drug: 280 mg Arikayce™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Study: NCT00775138
Drug: Matching Placebo for Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Study: NCT00775138
Drug: 560 mg Arikayce™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Study: NCT03964350
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The 0.8 g/kg body weight dose of gelatin alcohol will be divided into an average of 10 servings of 0.08 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.~The 0.4 g/kg body weight dose of gelatin alcohol will be divided into an average of 5 servings of 0.08 g/kg each. The 0.4 g/kg dose is equivalent to 2 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.
Study: NCT01156857
Drug: PGL4001, progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets).
Study: NCT03327740
Drug: DTG based ARV regimen with ABC
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARV regimens containing DTG and ABC
Study: NCT03327740
Drug: DTG based ARV regimen without ABC
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG based ARV regimens that do not contain ABC
Study: NCT03327740
Drug: RAL or EGV based ARV regimens with ABC
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAL or EGV based regimens containing ABC
Study: NCT03327740
Drug: RAL or EGV based regimens without ABC
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAL or EGV based ARV regimens that do not contain ABC
Study: NCT03327740
Drug: Any other DTG based ARV regimen as monotherapy
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
Study: NCT00166504
Drug: ezetimibe (+) simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin/ezetimibe 10/20 mg
Study: NCT01419236
Drug: Testosterone Solution 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered topically
Study: NCT01419236
Drug: Placebo Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered topically
Study: NCT02209714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04504734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg tablets
Study: NCT01131507
Drug: EUR-1008 (APT-1008)
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.
Study: NCT01964651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo orally administered once daily for 10 days.
Study: NCT02831894
Drug: 25% Hypnotic Medication Taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 20 week blinded tapering period.
Study: NCT02831894
Drug: 10% Hypnotic Medication Taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will have their soporific hypnotic medication dosage reduced by 10% every two weeks during a 20 week blinded tapering period.
Study: NCT01601093
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
Study: NCT01601093
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
Study: NCT02939573
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Randomized to azathioprine 2 mg/kg/day
Study: NCT02392429
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given anthracycline IV
Study: NCT02746081
Drug: BAY1436032
Approvals — FDA: no, EMA: no, PMDA: no
Description: The selected starting dose of BAY1436032 is 300 mg/day (150 mg BID) to be administered orally continuously in tablet form in 21-day cycles. Adjustments to this schedule may be made if warranted by information collected during the course of the study. The maximum feasible dose of BAY1436032 is expected to be 3000 mg/day.
Study: NCT00848172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical capsules
Study: NCT04335552
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5
Study: NCT02300922
Drug: Antibody TF2
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
Study: NCT02300922
Drug: 90-Y-IMP-288
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
Study: NCT02300922
Drug: 111-In-IMP-288
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
Study: NCT02249663
Drug: Dymista™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 137/50 mcg Nasal Spray
Study: NCT00181168
Drug: Euthyroid Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.
Study: NCT01775501
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT01775501
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT02151864
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
Study: NCT00520949
Drug: Cebes (colloidal bismuth subcitrate)
Normalized name: N'ICE Cubes 8 MG Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: colloidal bismuth subcitrate 240 mg b.i.d
Study: NCT00520949
Drug: Esso (esomeprazole)
Approvals — FDA: no, EMA: no, PMDA: no
Description: esomeprazole 40 mg b.i.d for 14 days
Study: NCT00202280
Drug: Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04046848
Drug: OCTA101
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCTA101 is composed of OCTA8 (human-cl rhFVIII - Nuwiq Intermediate 2 Q-Eluate) and OCTA12 (recombinant human VWF fragment dimer).
Study: NCT03582176
Drug: Lactose Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule by mouth twice per day
Study: NCT04199351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 171 placebo
Study: NCT02177695
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate, 30 mg/m2, IV (in the vein) on Days 1 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
Study: NCT02177695
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin, 30 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
Study: NCT04540185
Drug: NA-831
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: NA-831 30 mg of NA-831 in a capsule administered orally
Study: NCT04540185
Drug: Comparable Placebo of drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 30 mg in a capsule administered orally
Study: NCT03190174
Drug: Nab-Rapamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of ABI-009 will be given IV over 30 min for 2 of every 3 weeks beginning Day 8 Cycle 2. Only nivolumab will be given in Cycle 1. At Dose Level 1, 3-6 patients will receive 56 mg/m\^2; at Dose Level 2, 3-6 six patients will receive 75 mg/m\^2; and at Dose Level 3, 3-6 patients will receive 100 mg/m\^2.
Study: NCT01173874
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
Study: NCT01520727
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
Study: NCT01520727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose
Study: NCT02965963
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00628680
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
Study: NCT01474993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 subjects will be randomly selected to receive inactive placebo (Gelcaps identical in appearance to that of active medication and containing microcrystalline cellulose)
Study: NCT02965963
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02443688
Drug: CTX-4430
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02443688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00568295
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
Study: NCT00568295
Drug: Rofecoxib
Normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
Study: NCT00568295
Drug: Rofecoxib
Normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
Study: NCT01691534
Drug: Rifafour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifafour e-275 mg dosed by weight
Study: NCT03891706
Drug: tumor-specific TCR-T cells
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: On day 0 and day 14, 0.5-5x10\^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.
Study: NCT01416259
Drug: Withdraw treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00492999
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00492999
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02870738
Drug: Bladder Instillations
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution of heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be instilled into the bladder with a urinary catheter
Study: NCT03161015
Drug: GBT440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01903096
Drug: Primary Care Treatment As Usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
Study: NCT02117024
Drug: Metronomic Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
Study: NCT02117024
Drug: Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~* Vinorelbine~* Erlotinib~* Gemcitabine~* Paclitaxel~* Docetaxel~* Pemetrexed
Study: NCT03864783
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo:~Contains same ingredients as Meriva®, apart from curcumin. Similar in appearance to Meriva®.
Study: NCT00463814
Drug: AZD6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of AZD6244 as described in arm description.
Study: NCT00474123
Drug: Simvastatin 80 mg/day for 6 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg/day, single dose, for 6 weeks.
Study: NCT00474123
Drug: Ezetimibe 10 mg / Simvastatin 20 mg
Normalized name: ezetimibe 10 MG / simvastatin 20 MG [Vytorin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg / Simvastatin 20 mg~Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks
Study: NCT01077310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
Study: NCT00316212
Drug: INS50589 Intravenous Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00772538
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01779830
Drug: LY2624803 - Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as capsules.
Study: NCT01779830
Drug: Placebo - Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as capsules.
Study: NCT01779830
Drug: Placebo - Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as tablets.
Study: NCT04484610
Drug: Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain
Normalized name: Arthricare for Women Pain Relieving Nighttime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist eLearning modules, support tools and resources to promote assessing and dispensing appropriate opioid quantities for acute pain.
Study: NCT00808132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule, placebo (over-encapsulated), once a day for one year.
Study: NCT00531466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet orally three times a day for 28 days
Study: NCT01229098
Drug: LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks
Study: NCT03547908
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food
Study: NCT03547908
Drug: Placebo to match DTG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily, without regard to food
Study: NCT02944110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of placebo tablets
Study: NCT00914849
Drug: AMD3100
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01098435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing lactose and no active drug for daily oral administration
Study: NCT01152255
Drug: MK6186
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose \<= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose \<= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)
Study: NCT01152255
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets taken orally for seven day
Study: NCT03346538
Drug: Continuous infusion high-dose MCI-186
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT03346538
Drug: Continuous infusion placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT03346538
Drug: Approved dosing regimen MCI-186
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT03346538
Drug: Approved dosing regimen placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT00841854
Drug: tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tetracycline 500mg qid
Study: NCT00352027
Drug: Adriamycin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
Study: NCT00352027
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
Study: NCT01536886
Drug: LEO 90100
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04269629
Drug: Insect Venom
Normalized name: insect venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive insect venom immunotherapy. The frequency of systemic side-effects is recorded and compared between patients under antihypertensive treatment and patients not taking antihypertensive drugs.
Study: NCT03516123
Drug: CS3006
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s).
Study: NCT02872090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03698695
Drug: THN 201
Approvals — FDA: no, EMA: no, PMDA: no
Description: THN 201: Donepezil 5 mg and Mefloquine 10 mg/d
Study: NCT03698695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil placebo and Mefloquine placebo
Study: NCT03700424
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution of 0.90% w/v of sodium chloride (NaCl) in water
Study: NCT01522391
Drug: DPK-060 1% ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2